25 terminated. 25 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 25 | Terminated 25 |
| Phase 2 | 3 | Terminated 3 |
Follow Colitis: new trials by email Literature Review of Colitis trials Research Report on Colitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A First-in-Human Study of BB-TL1A-VIAL-HLE in Healthy Adults and People With Ulcerative Colitis BB-TL1A-VIAL-HLE - Ulcerative Colitis (UC) | Phase 1 | Terminated | Vial Australia Pty Ltd | 16 | 2025-06-23 | 2026-01-22 |
| A Study of NP-201 Acetate Injection in Healthy Adult Volunteers and in Patients With Mild-To-Moderate Active Ulcerative Colitis NP-201 acetate injection (Part A), Placebo - Healthy Adult Volunteers, Active Ulcerative Colitis | Phase 1 | Terminated | NIBEC Co., Ltd. | 35 | 2024-11-25 | 2026-06-23 |
| Study of ExoFlo for the Treatment of Medically Refractory Ulcerative Colitis ExoFlo - Ulcerative Colitis, Inflammatory Bowel Diseases | Phase 1 | Terminated | Direct Biologics, LLC | 4 | 2022-12-19 | 2025-02-11 |
| A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative Colitis PF-07054894, Placebo - Ulcerative Colitis | Phase 1 | Terminated | Pfizer | 44 | 2022-11-07 | 2026-02-25 |
| Efficacy and Safety of Rectally Administered BBT-401-1S in Subjects With Ulcerative Colitis BBT-401-1S - Ulcerative Colitis | Phase 1 | Terminated | Bridge Biotherapeutics, Inc. | 2 | 2021-06-01 | 2021-10-01 |
| Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC) Remestemcel-L, Placebo - Ulcerative Colitis | Phase 1 / Phase 2 | Terminated | The Cleveland Clinic | 7 | 2020-11-10 | 2026-04-16 |
| A Study of JNJ-66525433 in Healthy Participants and Participants With Ulcerative Colitis JNJ-66525433, Placebo - Healthy, Colitis, Ulcerative | Phase 1 | Terminated | Janssen Research & Development, LLC | 82 | 2020-07-01 | 2025-02-03 |
| Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease Nivolumab - Autoimmune Diseases, Non-small Cell Lung Cancer | Phase 1 | Terminated | Alliance Foundation Trials, LLC. | 7 | 2019-06-27 | 2023-02-15 |
| Double-Blinded, Placebo-Controlled Phase 1b Study for Safety, PK, Efficacy, PD of RO7049665 in Participants With Ulcerative Colitis (UC) RO7049665, Placebo - Ulcerative Colitis | Phase 1 | Terminated | Hoffmann-La Roche | 45 | 2019-05-13 | 2024-02-15 |
| Study to Evaluate APVO210 in Healthy Subjects, Patients With Psoriasis, and Patients With Ulcerative Colitis APVO210, Placebo - Psoriasis, Ulcerative Colitis | Phase 1 | Terminated | Aptevo Therapeutics | 85 | 2019-03-18 | 2021-05-19 |
| A Study of Niclosamide Enemas in Subjects With Active Ulcerative Proctitis or Ulcerative Proctosigmoiditis Niclosamide - Ulcerative Colitis, Ulcerative Proctitis | Phase 1 / Phase 2 | Terminated | Entero Therapeutics | 27 | 2018-05-15 | 2022-11-29 |
| A Phase I Study of Etrolizumab Followed by Open-Label Extension and Safety Monitoring in Pediatric Patients With Moderate to Severe Ulcerative Colitis or Moderate to Severe Crohn's Disease Etrolizumab - Ulcerative Colitis, Crohn's Disease | Phase 1 | Terminated | Hoffmann-La Roche | 24 | 2018-03-27 | 2024-12-27 |
| HMPL004-6599 Phase I Dose-escalating Study HMPL004-6599, Placebo - Ulcerative Colitis, Crohn Disease | Phase 1 | Terminated | Nutrition Science Partners Limited | 32 | 2018-03-20 | 2019-12-17 |
| A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis Ustekinumab IV Infusion, Ustekinumab SC Injection, Midazolam 2 mg - Crohn Disease, Ulcerative Colitis | Phase 1 | Terminated | Janssen Research & Development, LLC | 28 | 2018-02-02 | 2025-08-21 |
| Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis MDGN-002 - Crohn Disease, Ulcerative Colitis | Phase 1 | Terminated | Avalo Therapeutics, Inc. | 8 | 2017-07-14 | 2024-02-26 |
| Single Ascending Dose and Multiple Ascending Dose Study in Healthy Participants and Proof of Mechanism Study in Patients With Ulcerative Colitis BMS-986184, Placebo matching BMS-986184 - Healthy Volunteers, Ulcerative Colitis | Phase 1 | Terminated | Bristol-Myers Squibb | 7 | 2016-09-14 | 2017-10-20 |
| Fecal Transplantation for Inflammatory Bowel Disease Fecal microbial l transplantation - Inflammatory Bowel Disease | Phase 1 | Terminated | Meir Medical Center | 9 | 2015-04-01 | 2016-06-14 |
| Safety and Tolerability Study of GSK2586184 in Patients With Moderate to Severely Active Ulcerative Colitis. GSK2586184 400mg - Colitis, Ulcerative | Phase 1 | Terminated | GlaxoSmithKline | 2 | 2013-12-20 | 2020-10-09 |
| A Pilot and Feasibility Study of Fecal Microbiota Transplantation for Ulcerative Colitis fecal microbiota transplantation - Ulcerative Colitis | Phase 1 | Terminated | University of Chicago | 1 | 2013-06-01 | 2016-08-24 |
| Bone Marrow Stromal Cells for Inflammatory Bowel Diseases Bone Marrow Stromal Cell (BMSC) Infusion - Inflammatory Bowel Disease | Phase 1 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 8 | 2013-01-27 | 2019-03-29 |
Showing 20 of 25. Sign in to see all of them.
Colitis, Ulcerative (25) · Inflammatory Bowel Diseases (7) · Crohn Disease (6) · Psoriasis (2) · Arthritis, Rheumatoid (1) · Autoimmune Diseases (1) · Carcinoma, Non-Small-Cell Lung (1) · Diarrhea (1) · Giant Cell Arteritis (1) · Ileitis (1) · Infections (1) · Inflammation (1) · Lupus Erythematosus, Systemic (1) · Multiple Sclerosis (1)
Colonic Diseases (25) · Digestive System Diseases (25) · Gastroenteritis (25) · Gastrointestinal Diseases (25) · Intestinal Diseases (25) · Inflammatory Bowel Diseases (18) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Skin Diseases (2) · Skin Diseases, Papulosquamous (2) · Skin and Connective Tissue Diseases (2) · Arteritis (1) · Arthritis (1) · Autoimmune Diseases of the Nervous System (1)
Antibodies (1) · Caffeine (1) · Clotrimazole (1) · Dextromethorphan (1) · Fecal Microbiota Transplantation (1) · GSK2586184 (1) · Mesalamine (1) · Midazolam (1) · Niclosamide (1) · Nivolumab (1) · Omeprazole (1) · Vitamin K (1) · Warfarin (1) · abrilumab (1) · etrolizumab (1)
GlaxoSmithKline (2) · Hoffmann-La Roche (2) · Janssen Research & Development, LLC (2) · Alliance Foundation Trials, LLC. (1) · Amgen (1) · Aptevo Therapeutics (1) · Avalo Therapeutics, Inc. (1) · Bridge Biotherapeutics, Inc. (1) · Bristol-Myers Squibb (1) · Direct Biologics, LLC (1) · Entero Therapeutics (1) · Meir Medical Center (1) · NIBEC Co., Ltd. (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Nutrition Science Partners Limited (1)
United States (12) · Australia (6) · Germany (3) · Belgium (2) · Georgia (2) · Moldova (2) · New Zealand (2) · Poland (2) · United Kingdom (2) · Hungary (1) · Israel (1) · Italy (1) · Netherlands (1) · Spain (1) · Ukraine (1)
Amy Lightner (1) · Bill Arana (1) · David Schaaf, MD (1) · Ivan J Fuss, M.D. (1) · James Pennington, M.D. (1) · Michele DeSciscio, Dr. (1) · Paul A. Rufo, MD, MMSc (1)
2017 (3), 2016 (1), 2018 (1)